Lupin has obtained approval from the USFDA to market a generic form of an HIV medication. The approved drug, equivalent to Symtuza tablets, positions Lupin as the exclusive first-to-file. The tablets ...

In the past two days, Lupin stock has surged 8 per cent after the pharmaceutical company received tentative approval from the US Food and Drug Administration (USFDA) to market generic HIV combination ...

Stocks trading ex-dividend: Castrol India, Coromandel International (Rs 6), GTV Engineering (Rs 0.5), Indian Metals & Ferro ...

Lupin gained 3.66% to Rs 2,188 after the company announced that it has received a tentative approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Darunavir, Cobicistat, ...

According to IQVIA MAT December 2024, this drug will generate a U.S. market sales revenue of $1,374 million. Lupin is the first-to-file applicant for this generic product. Being the first-to-file ...

Lupin receives tentative USFDA approval for its generic HIV treatment, combining Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. The drug, equivalent to Janssen's Symtuza ...

Drug maker Lupin Ltd confirmed on Tuesday that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of a combination HIV treatment. The company ...

Lupin has received USFDA approval for its generic version of Symtuza, a medication for HIV. The product is estimated to have annual sales of USD 1.374 billion in the US. New Delhi, Feb 3 (PTI) Drug ...

Lupin has received approval from the Food and Drug Administration for ipratropium bromide nasal solution (nasal spray), 0.06%, which is a generic of Boehringer Ingelheim's Atrovent Nasal Spray, 0.06%.

Lupin also shared that it has received FDA approval for sacubitril and valsartan tablets, 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg, which is the generic of Novartis’ Entresto.